BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 1963219)

  • 1. [Ductal carcinoma in situ: steroid receptors and proliferation kinetics].
    Ronay G; Sponsel N; Tulusan AH
    Pathologe; 1990 Nov; 11(6):327-31. PubMed ID: 1963219
    [No Abstract]   [Full Text] [Related]  

  • 2. [Progesterone receptors in breast cancer. Comparison of immunohistochemical with biochemical receptor analysis. Relation between hormone receptor content and growth fraction (Ki-67)].
    Ronay G; Sponsel N; Merkle E; Tulusan AH
    Pathologe; 1990 Jan; 11(1):4-9. PubMed ID: 2156252
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cell receptors and proliferation markers in breast cancer].
    Czerwenka KF; Schön HJ; Zeillinger R; Kubista E; Spona J
    Gynakol Rundsch; 1989; 29 Suppl 2():400-1. PubMed ID: 2558992
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of transport conditions on biochemically and immunohistochemically determined steroid hormone receptor content in breast cancer].
    Remmele W; Schicketanz KH
    Pathologe; 1993 Jan; 14(1):21-4. PubMed ID: 8383846
    [No Abstract]   [Full Text] [Related]  

  • 5. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Morphometric correlates of the steroid receptor content in invasive ductal breast cancers].
    Mattfeldt T; Neurohr W; Müller A; Klinga K
    Verh Dtsch Ges Pathol; 1985; 69():350-5. PubMed ID: 3006385
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparison of the receptor content and growth fraction of breast cancers and their axillary lymph node metastases].
    Fleige B; Pickartz H; Stein H
    Pathologe; 1989 Jan; 10(1):12-5. PubMed ID: 2646629
    [No Abstract]   [Full Text] [Related]  

  • 8. [Quantitative determination of steroid hormone receptors in breast cancer tissue outside tumor centers].
    Prechtel D; Prechtel K
    Pathologe; 1993 Jan; 14(1):16-20. PubMed ID: 8451222
    [No Abstract]   [Full Text] [Related]  

  • 9. [Immunohistochemical detection of estrogen and progesterone receptors in paraffin sections].
    Snijders M; Theunissen P; Debets-Te Baerts M; Koudstaal J
    Pathologe; 1990 Jul; 11(4):236-9. PubMed ID: 2204912
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor properties of primary tumors and local recurrence of breast cancer].
    Torsten U; Opri F; Moreno-Richter I; Weitzel HK
    Zentralbl Gynakol; 1993; 115(3):99-104. PubMed ID: 8385409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone receptor status in breast cancer in comparison with histologic tumor type].
    Kasch R; Meissner J; Haack D; Neumann S
    Zentralbl Gynakol; 1987; 109(24):1493-6. PubMed ID: 2831683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of the proliferative activity of breast cancer for prognosis and therapy].
    Pickartz H
    Z Arztl Fortbild (Jena); 1991 Oct; 85(20):993-4. PubMed ID: 1776291
    [No Abstract]   [Full Text] [Related]  

  • 14. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
    Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
    Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Morphologic and morphometric parameters of infiltrating duct carcinoma of the breast and receptor state in fluorescence: correlations in 104 cases (1983 case survey)].
    Tunesi G; Anselmi L; Bandelloni R; Gambini C; Reale A; Sementa AR; Bronzini E
    Pathologica; 1985; 77(1049):251-8. PubMed ID: 3008066
    [No Abstract]   [Full Text] [Related]  

  • 16. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
    Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
    Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunohistochemical detection of progesterone receptors in breast cancer. Comparison of antibodies mPRI and PR-ICA].
    Weikel W; Rosenthal H; Beck T; Mitze M
    Pathologe; 1990 Mar; 11(2):85-8. PubMed ID: 2184428
    [No Abstract]   [Full Text] [Related]  

  • 18. [Correlations between receptor state and various clinico-morphological parameters: evaluation of circa 2000 cases of breast tumors].
    Lampertico P; Stagni F
    Pathologica; 1985; 77(1049):281-97. PubMed ID: 3008068
    [No Abstract]   [Full Text] [Related]  

  • 19. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
    Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
    Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
    [No Abstract]   [Full Text] [Related]  

  • 20. [Value of steroid hormone receptors as prognostic factors in breast, ovarian and endometrial cancer].
    von Minckwitz G; Kaufmann M
    Gynakologe; 1993 Apr; 26(2):100-6. PubMed ID: 8508979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.